Innovating Works

XENTECH SAS

Desconocido
Maxima Butterfly: From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network XENTECH SAS participó en un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a gr...
2022-10-10 - 2027-12-31 | Financiado
ITCC-P4: ITCC Pediatric Preclinical POC Platform Sofia ref. 116064 XENTECH SAS participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant s...
2017-05-18 - 2023-12-31 | Financiado
ChiLTERN: Children s Liver Tumour European Research Network XENTECH SAS participó en un H2020: H2020-PHC-2014-2015 Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in...
2015-12-07 - 2021-12-31 | Financiado
EUROCSCTRAINING: EUROCANCER STEMCELL TRAINING NETWORK XENTECH SAS participó en un FP7: The recent identification of tumor initiating (TIC) or cancer stem cells (CSC) has opened a new area of research for scientists interested i...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.